Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Lung Cancer

Free Subscription Articles published in Cancer Chemother Pharmacol Retrieve available abstracts of 27 articles: HTML format

Single Articles

August 2026
1. GROOT BEUMER KWM, Durlinger EMJ, Zielhuis SWJ, Ter Heine R, et al
   Dosing challenges for chemotherapy and immunotherapy in congenital achondroplasia: a case report and literature review.
   Cancer Chemother Pharmacol. 2026;96:82.
   PubMed     Abstract available
   
   
   July 2026
2. MAKINO Y, Ogawa T, Makihara-Ando R, Sakiyama N, et al
   Development of a simplified population pharmacokinetic-pharmacodynamic framework for exposure-informed risk stratification of neutropenia during amrubicin treatment.
   Cancer Chemother Pharmacol. 2026;96:81.
   PubMed     Abstract available
   
   
   
3. NAKAJO M, Uchino T, Asada K, Hatta I, et al
   Composition and structure of stratum corneum intercellular lipids in patients with osimertinib-induced hand-foot syndrome.
   Cancer Chemother Pharmacol. 2026;96:68.
   PubMed     Abstract available
   
   
   June 2026
4. BHARATH P, Iyer S, Velu AV, Kumar DT, et al
   ALK rearrangements and resistance mutations in non-small cell lung cancer: molecular mechanisms and therapeutic implications.
   Cancer Chemother Pharmacol. 2026;96:66.
   PubMed     Abstract available
   
   
   April 2026
5. ALAMILLA-GARCIA G, Tahuahua-Flores O, Soriano-Maya A, Caballe-Perez E, et al
   Durable response to brigatinib in a ROS1 fusion-positive inflammatory myofibroblastic tumor.
   Cancer Chemother Pharmacol. 2026;96:37.
   PubMed     Abstract available
   
   
   January 2026
6. HUANG H, Wang J
   Association between modifications in intravenous chemotherapy dose and disease-free survival and related influencing factors in lung cancer patients: a retrospective study based on inverse probability weighting.
   Cancer Chemother Pharmacol. 2026;96:6.
   PubMed     Abstract available
   
   
   December 2025
7. GRACIA M, Marsili S, Vintejoux J, Gladieff L, et al
   Benefit of plasma cystatin C for carboplatin individual dosing in a patient with spinal amyotrophy.
   Cancer Chemother Pharmacol. 2025;95:124.
   PubMed     Abstract available
   
   
   November 2025
8. YAN Y, Zheng X, Zhao X, Si X, et al
   Afatinib for a non-small cell lung cancer patient in hemodialysis: A case report and literature review.
   Cancer Chemother Pharmacol. 2025;95:112.
   PubMed     Abstract available
   
   
   
9. ZHOU Y, Huang W, Hang X, He Y, et al
   Inhibiting TROP2 in advanced non-small-cell lung cancer with sacituzumab govitecan, datopotamab deruxtecan, and sacituzumab tirumotecan: similarities and differences.
   Cancer Chemother Pharmacol. 2025;95:106.
   PubMed     Abstract available
   
   
   
10. TER HEINE R, van den Bosch BJC, van Geel RM, van Geffen WH, et al
    Optimizing lazertinib therapy through GSTM1 genotyping: a strategy to reduce excess drug exposure and potential toxicity.
    Cancer Chemother Pharmacol. 2025;95:105.
    PubMed     Abstract available
    
    
    June 2025
11. LI H, Pu Z, Fang J
    Effect of Metformin on vascular endothelial injury in patients with non-small cell lung cancer treated with chemotherapy combined with bevacizumab.
    Cancer Chemother Pharmacol. 2025;95:59.
    PubMed     Abstract available
    
    
    March 2025
12. YOKOTA H, Sato K, Sakamoto S, Okuda Y, et al
    Influence of interleukin-6 on the pharmacokinetics and pharmacodynamics of osimertinib in patients with non-small cell lung cancer.
    Cancer Chemother Pharmacol. 2025;95:49.
    PubMed     Abstract available
    
    
    January 2025
13. FUNAISHI K, Yamaguchi K, Tanahashi H, Kurose K, et al
    HMGB1 assists the predictive value of tumor PD-L1 expression for the efficacy of anti-PD-1/PD-L1 antibody in NSCLC.
    Cancer Chemother Pharmacol. 2025;95:28.
    PubMed     Abstract available
    
    
    
14. CHENG CY, Chuang WC, Lin CP, Li CH, et al
    Endoglin as a predictive biomarker for pemetrexed sensitivity in non-small-cell lung cancer: a cellular study.
    Cancer Chemother Pharmacol. 2025;95:20.
    PubMed     Abstract available
    
    
    December 2024
15. GEZELIUS E, Planck M, Hazem B, Nagpal S, et al
    Intrathecal pemetrexed for leptomeningeal metastases in a patient with ALK-rearranged lung adenocarcinoma: a case report.
    Cancer Chemother Pharmacol. 2024;95:6.
    PubMed     Abstract available
    
    
    
16. DE ROUW N, Beunders R, Hartmann O, Schulte J, et al
    A comparison of the renal function biomarkers serum creatinine, pro-enkephalin and cystatin C to predict clearance of pemetrexed.
    Cancer Chemother Pharmacol. 2024;94:799-806.
    PubMed     Abstract available
    
    
    September 2024
17. LIN L, van der Noort V, Steeghs N, Ruiter G, et al
    A joint model of longitudinal pharmacokinetic and time-to-event data to study exposure-response relationships: a proof-of-concept study with alectinib.
    Cancer Chemother Pharmacol. 2024;94:453-459.
    PubMed     Abstract available
    
    
    July 2024
18. YAMAMOTO N, Koyama T, Sato J, Yoshida T, et al
    Phase I study of the anti-TIGIT antibody tiragolumab in combination with atezolizumab in Japanese patients with advanced or metastatic solid tumors.
    Cancer Chemother Pharmacol. 2024;94:109-115.
    PubMed     Abstract available
    
    
    April 2024
19. XU X, Liu Y, Gong Q, Ma L, et al
    PARP1 promotes EGFR-TKI drug-resistance via PI3K/AKT pathway in non-small-cell lung cancer.
    Cancer Chemother Pharmacol. 2024 Apr 12. doi: 10.1007/s00280-024-04668.
    PubMed     Abstract available
    
    
    
20. URYU K, Imamura Y, Shimoyama R, Mase T, et al
    Prognostic impact of concomitant pH-regulating drugs in patients with non-small cell lung cancer receiving epidermal growth factor receptor tyrosine kinase inhibitors: the Tokushukai REAl-world Data project 01-S1.
    Cancer Chemother Pharmacol. 2024 Apr 8. doi: 10.1007/s00280-024-04666.
    PubMed     Abstract available
    
    
    March 2024
21. HUO H, Feng Y, Tang Q
    Correction to: Inhibition of proteinase-activated receptor 2 (PAR2) decreased the malignant progression of lung cancer cells and increased the sensitivity to chemotherapy.
    Cancer Chemother Pharmacol. 2024 Mar 26. doi: 10.1007/s00280-024-04646.
    PubMed    
    
    
    February 2024
22. MA X, Sun Z, Chen H, Cao L, et al
    18beta-glycyrrhetinic acid suppresses Lewis lung cancer growth through protecting immune cells from ferroptosis.
    Cancer Chemother Pharmacol. 2024 Feb 21. doi: 10.1007/s00280-024-04639.
    PubMed     Abstract available
    
    
    January 2024
23. YU F, Huo H, Tang Q
    Inhibition of proteinase-activated receptor 2 (PAR2) decreased the malignant progression of lung cancer cells and increased the sensitivity to chemotherapy.
    Cancer Chemother Pharmacol. 2024 Jan 4. doi: 10.1007/s00280-023-04630.
    PubMed     Abstract available
    
    
    
24. LI MY, Zhang J, Lu X, Zhou D, et al
    Ivermectin induces nonprotective autophagy by downregulating PAK1 and apoptosis in lung adenocarcinoma cells.
    Cancer Chemother Pharmacol. 2024;93:41-54.
    PubMed     Abstract available
    
    
    November 2023
25. WANG X, Gu S, Wen J, Zhang L, et al
    Association between chemotherapy-induced myelosuppression and curative efficacy of 2-cycle chemotherapy in small cell lung cancer.
    Cancer Chemother Pharmacol. 2023 Nov 5. doi: 10.1007/s00280-023-04608.
    PubMed     Abstract available
    
    
    
26. MA Y, Chen Q, Zhang Y, Xue J, et al
    Pharmacokinetics, safety, tolerability, and feasibility of apatinib in combination with gefitinib in stage IIIB-IV EGFR-mutated non-squamous NSCLC: a drug-drug interaction study.
    Cancer Chemother Pharmacol. 2023;92:411-418.
    PubMed     Abstract available
    
    
    September 2023
27. CHENG M, Yang F, Yang Y, Gao X, et al
    Correlation analysis between camrelizumab trough concentration levels and efficacy or safety in East Asian patients with advanced lung cancer.
    Cancer Chemother Pharmacol. 2023 Sep 23. doi: 10.1007/s00280-023-04590.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum